NewLimit raises $682M to pursue new class of anti-aging drugs
NewLimit, a biotech startup based in South San Francisco, announced it secured $682 million in funding.
The round was led by venture firms including Kleiner Perkins, Founders Fund, Dimension Capital, Eli Lilly Ventures, and Thrive Capital. Co-founders Jacob Kimmel (CEO), Brian Armstrong and Blake Byers will use the capital to explore a novel class of anti-aging therapeutics.
The company aims to go beyond existing approaches such as Yamanaka factors, targeting mechanisms that could extend healthy lifespan. The sizable investment underscores investor interest in aging-related drug development.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugs”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that